To improve the lives of patients by creating & developing innovative antibody products

**Foundational Products:**
Solid Financial Base, Significant potential

**Our Own Clinical Pipeline**
Potential first-in-class / Best-in-class
Tisotumub vedotin¹, enapotamab vedotin, HexaBody⁰-DR5/DR5, DuoBody⁰-CD3xCD20, DuoBody-PD-L1x4-1BB², DuoBody-CD40x4-1BB²
2019 Projected IND/CTA: DuoHexaBody⁰-CD37

**Partner Programs:**
Additional Shots on Goal
10 in clinical development with partners; royalty streams for Genmab should they come to market. Includes 6 DuoBody products with Janssen

**Technologies & Pre-Clinical**
R&D Engine: Powerhouse of Innovation
DuoBody, HexaBody, DuoHexaBody, HexElect⁰ platforms & rich-pre-clinical pipeline

**Our Three-pronged Strategy**
- **Focus on core competence**
- **Turn science into medicine**
- **Build a profitable & successful biotech**

**Our Vision**
By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks-off antibodies

**Revenue**
MDDK (~MUSD⁴)

<table>
<thead>
<tr>
<th>2019 Guidance</th>
<th>DKK</th>
<th>~USD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Income Statement</strong></td>
<td>DKKM</td>
<td>USD³</td>
</tr>
<tr>
<td>Revenue</td>
<td>5,100</td>
<td>761</td>
</tr>
<tr>
<td>Operating expenses</td>
<td>(2,750)</td>
<td>(410)</td>
</tr>
<tr>
<td>Operating income</td>
<td>2,350</td>
<td>351</td>
</tr>
</tbody>
</table>

¹USD 1.00 = DKK 6.70

*In collaboration with Seattle Genetics *In collaboration with BioNTech.

For more information/contact: genmab.com/in@genmab.com

For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s final prospectus for its U.S. public offering and listing and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.

Nov 6, 2019
**Genmab Proprietary** Products and innovative Pre-clinical Pipeline

<table>
<thead>
<tr>
<th>Product</th>
<th>Disease Indications</th>
<th>Most Advanced Dev. Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tisotumab vedotin</td>
<td>Cervical cancer</td>
<td>Pre-clin., I, II, III, IV, Launch</td>
</tr>
<tr>
<td></td>
<td>Ovarian cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Solid tumors</td>
<td>I, II, III, IV, Launch</td>
</tr>
<tr>
<td>Enapotamab vedotin</td>
<td>Solid tumors</td>
<td>Pre-clin., I, II, III, IV, Launch</td>
</tr>
<tr>
<td>HexaBody-DR5/DR5</td>
<td>Solid tumors</td>
<td>Pre-clin., I, II, III, IV, Launch</td>
</tr>
<tr>
<td>DuoBody-CD3xCD20</td>
<td>Hematological malignancies</td>
<td>Pre-clin., I, II, III, IV, Launch</td>
</tr>
<tr>
<td>DuoBody-PD-L1x4-1BB</td>
<td>Solid tumors</td>
<td>Pre-clin., I, II, III, IV, Launch</td>
</tr>
<tr>
<td>DuoBody-CD40x4-1BB</td>
<td>Solid tumors</td>
<td>Pre-clin., I, II, III, IV, Launch</td>
</tr>
<tr>
<td>IND / CTA</td>
<td>DuoHexaBody-CD37</td>
<td>Pre-clin., I, II, III, IV, Launch</td>
</tr>
</tbody>
</table>

* Certain products in co-development, partners as noted.

**Marketed Partnered Products**

<table>
<thead>
<tr>
<th>Product</th>
<th>Disease Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daratumumab</td>
<td>MM&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>AL Amyloidosis</td>
</tr>
<tr>
<td></td>
<td>Non-MM blood cancers</td>
</tr>
<tr>
<td>Ofatumumab</td>
<td>CLL&lt;sup&gt;5,6&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>RMS</td>
</tr>
</tbody>
</table>

**Partner Programs**

<table>
<thead>
<tr>
<th>Product</th>
<th>Disease Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teprotumumab</td>
<td>Thyroid eye disease</td>
</tr>
<tr>
<td>HuMax-IL8</td>
<td>Advanced cancers</td>
</tr>
<tr>
<td>Camidanumab tesirine</td>
<td>RR Hodgkin lymphoma</td>
</tr>
<tr>
<td></td>
<td>Solid tumors</td>
</tr>
<tr>
<td>JNJ-61186372</td>
<td>NSCLC</td>
</tr>
<tr>
<td>JNJ-63791178</td>
<td>AML</td>
</tr>
<tr>
<td>JNJ-6407957</td>
<td>RRMM</td>
</tr>
<tr>
<td>JNJ-64407564</td>
<td>RRMM</td>
</tr>
<tr>
<td>JNJ-67571244</td>
<td>RR AML or MDS</td>
</tr>
<tr>
<td>JNJ-6389081</td>
<td>Solid tumors</td>
</tr>
<tr>
<td>Lu AF82422</td>
<td>Parkinson’s disease</td>
</tr>
<tr>
<td></td>
<td>HuMab &amp; DuoBody</td>
</tr>
</tbody>
</table>

**Products & Technologies**

**Tisotumab vedotin**
- Antibody-drug conjugate (ADC) in dev.
- to treat solid tumors
- Ph. II potential reg. study in cervical cancer
- Ph II studies in ovarian & other solid tumors
- 50:50 agreement w/ Seattle Genetics

**Enapotamab vedotin**
- ADC in development to treat solid tumors
- Ph I/II clinical study for multiple solid tumors

**HexaBody-DR5/DR5 (GEN1029)**
- Proprietary antibody therapeutic created w/ Genmab’s HexaBody technology
- Phase I/II clinical trial in solid tumors

**DuoBody-CD3xCD20 (GEN3013)**
- Proprietary bispecific antibody created w/ Genmab’s DuoBody technology
- Phase I/II clinical trial in B-cell malignancies

**DuoBody-PD-L1x4-1BB (GEN1046)**
- Bispecific antibody created w/ DuoBody tech
- First CTA filed in March 2019
- 50:50 agreement w/ BioNTech

**DuoBody-CD40x4-1BB (GEN1042)**
- Bispecific antibody created w/ DuoBody tech
- First CTA filed in March 2019
- 50:50 agreement w/ BioNTech

**DARZALEX (daratumumab)**
- First-in-class CD38 antibody
- Approved in certain territories for various multiple myeloma (MM) indications
- Multiple Ph III studies ongoing in MM, amyloidosis & Sub-Q formulation
- Collaboration w/ Janssen
- 2018 net sales by Janssen: $2,025M

**Arzerra (ofatumumab)**
- Human CD20 monoclonal antibody developed in collaboration w/ Novartis
- Approved in certain territories for various chronic lymphocytic leukemia (CLL) indications
- 2018 net sales by Novartis: $266M

**Ofatumumab (OMB157)**
- SubQ formulation in development to treat relapsing multiple sclerosis (RMS)
- Positive data from 2 Ph. III studies in RMS

**DuoBody Platform**
- Bispecific antibody technology platform
- Potential in cancer, autoimmune, infectious, cardiovascular, central nervous system diseases & hemophilia
- Multiple commercial & research collaborations

**HexaBody Platform**
- Enhanced potency antibody technology platform
- Broadly applicable technology that builds on natural antibody biology

**DuoHexaBody Platform**
- Antibody technology that combines DuoBody & HexaBody platforms
- Creates bispecific antibodies w/ target-mediated enhanced potency

**HexElect Platform**
- Antibody technology platform inspired by HexaBody platform
- Combines dual targeting w/ enhanced selectivity & potency

**Executive Management:**
- Jan G. J. van de Winkel, Ph.D. President & CEO
- David A. Eatwell, FCCA, EVP & CFO
- Judith Klimovsky M.D., EVP & CDO

**Founded:** 1999

**Exchanges:** CSE / Nasdaq

**Symbol:** GMAB

**Shares outstanding:** 65,018,173

**Market Cap as of Nov 6, 2019:** DKK 95B (USD 14,195M)

---

5 See local country prescribing information for precise indications

6 Jan. 22, 2018: Novartis announced intention to transition Arzerra from commercially available to limited availability via compassionate use programs in non-US markets.